Unknown Brain & Nervous System NIHR-supported project Cancer
Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692, and Ocrevus (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
About this grant
This summary is based on the grant title only — the full abstract was not available.
No substantive source abstract was published for this research project funded by NIHR.
Researchers
Basil Sharrack (Principal Investigator)
Related Research
Grants with similar aims, by meaning.
A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study To Evaluate The Efficacy, Safety And Pharmacokinetics Of A Higher Dose Of Ocrelizumab In Adults With Primary Progressive Multiple Sclerosis
An Open-label, single-arm study to evaluate the effectiveness and safety of ocrelizumab in patients with early stage relapsing remitting multiple sclerosis
Gavotte: A Phase 111B Multicenter, randomized, double-blind, controlled study to evaluate the efficacy, safety and pharmacokinetics of a higher dose of ocrelizumab in adults with primary progressive multiple sclerosis. (BN42083 Study to evaluate high dose Ocrelizumab in PPMS)
A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy Study To Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis
BN42083 GAVOTTE - A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study To Evaluate The Efficacy, Safety And Pharmacokinetics Of A Higher Dose Of Ocrelizumab In Adults With Primary Progressive Multiple Sclerosis
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know